Dr. Laila Alia Gharzai, MD

Dr. Gharzai practices at Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare.

Dr. Gharzai's NPI, 1003268954, was assigned on July 4, 2016. Dr. Gharzai graduated from University of Nebraska College of Medicine in 2016. Dr. Gharzai holds Illinois license 036.155764.

Dr. Gharzai's primary practice is Northwestern Memorial Hospital, at 251 E Huron St, Chicago, IL 60611 in Cook County. The practice phone is (312) 926-2000.

Dr. Gharzai's primary practice is Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare. Dr. Gharzai is also affiliated with Northwestern Medicine Central DuPage Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Gharzai to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gharzai practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Gharzai's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Gharzai's licenses on file in 2 states: Illinois and Nebraska.

CMS data shows 848 Medicare services from Dr. Gharzai across 14 procedure codes in 2024, for 113 Medicare patients. Medicare paid $62,504 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 113 Medicare patients who saw Dr. Gharzai in 2024. The largest group is 65 to 74, with 51 patients. 70% of them have high blood pressure, and 70% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gharzai's median patient age at 75, with 43% women.

In 2024, Dr. Gharzai wrote 59 Medicare Part D claims for 24 patients. 76% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $254 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Gharzai for performance year 2024, reported through an alternative payment model (APM). Dr. Gharzai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gharzai as offering telehealth.

Dmand AI links 44 papers to Dr. Gharzai, published from 2017 to 2025. 2025 was the busiest year, with 9. The most frequent topics are Head and Neck Neoplasms, Financial Stress and Squamous Cell Carcinoma of Head and Neck. Dr. Gharzai has published most often in JCO Oncol Pract. Dr. Gharzai's most frequent co-authors are Michelle L. Mierzwa, MD, Leila Jean Mady, MD, MPH, PhD and Katelyn Ostendorf Stepan, MD.

Dmand AI links Dr. Gharzai to 3 clinical trials, 3 of them phase 2/3 studies. 3 are still active or recruiting. Conditions studied include Nasopharyngeal Carcinoma, Oropharyngeal Neoplasms and Squamous Cell Carcinoma of Head and Neck. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 9 general payments to Dr. Gharzai from 6 drug and device companies from 2017 to 2021. Food and beverage make up the largest share, 100% of the total. RaySearch Laboratories AB (publ) paid the most, $485.

Dr. Gharzai graduated from University of Nebraska College of Medicine in 2016.